Janssen

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Janssen sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 10 completed later-stage tilt top decile by trial count

Janssen: 10 sponsored US clinical trials, none currently recruiting.

Janssen sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 2 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 2 trials.

Top-decile sponsor footprint

Janssen ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

10 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

10 total, page 1 of 1

COMPLETED Phase 2

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis

NCT01483599
COMPLETED

Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)

NCT00246194
COMPLETED NA

A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients

NCT00002438
COMPLETED NA

A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients With AIDS

NCT00002278
COMPLETED Phase 3

Evaluation of Galantamine in the Treatment of Alzheimer's Disease

NCT00000172
COMPLETED NA

Protocol For the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433)

NCT00002027
COMPLETED Phase 3

A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis

NCT00002159
COMPLETED NA

An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in HIV-Positive Subjects.

NCT00002133
COMPLETED NA

Study of Itraconazole in Patients With Advanced HIV Infection

NCT00002370
COMPLETED NA

A Study of Treatments for Fungal Infections of the Mouth and Throat in HIV-Infected Patients Who Have Had Success With Itraconazole But Not With Fluconazole

NCT00002341

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 2

Therapeutic Areas

HIV Infections 2
Histoplasmosis 1
Cryptosporidiosis 1
Alzheimer Disease 1

How the Janssen archive is shaped

10 indexed studies, none listed as recruiting (0% open); 10 completed (100%).

Phase mix: 2 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: HIV Infections (2 trials), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Janssen: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Janssen sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share JanssenAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Janssen sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Janssen sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Janssen page

10 registered trials is a research-attention snapshot, not an endorsement of Janssen or any single study.

  • None of Janssen's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • HIV Infections is the condition Janssen studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Janssen pipeline card: 10 registered trials from official public datasets.Report a data error.